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Abstract
Grapefruit juice is consumed widely in today's health conscious world as a protector against
cardiovascular diseases and cancers. It has however, been found to be an inhibitor of the intestinal
cytochrome P – 450 3A4 system, which is responsible for the first pass metabolism of many drugs.
The P – glycoprotein pump, found in the brush border of the intestinal wall which transports many
of these cytochrome P – 450 3A4 substrates, has also been implicated to be inhibited by grapefruit
juice. By inhibiting these enzyme systems, grapefruit juice alters the pharmacokinetics of a variety
of medications, leading to elevation of their serum concentrations. Most notable are its effects on
the calcium channel antagonist and the statin group of drugs. In the case of many drugs, the
increased serum concentration has been found to be associated with increased frequency of dose
dependent adverse effects. In this review, we have discussed the phytochemistry of grapefruit juice,
the various drugs involved in the drug – grapefruit juice eraction with their mechanisms of action
and have presented the clinical implications of these interactions.
Introduction
The grapefruit, thought to be a cross between an orange
and a shaddock, was developed in the West Indies in the
early 1700s and first introduced to Florida in the 1820s.
Since the early part of the 20th century, mutant strains of
white grapefruit have appeared with pink to slightly red-
dish colour, and have been propagated by citriculturists
into several strains of grapefruit. The three major types of
grapefruit that exist today are white, pink/red and ruby/rio
red varieties. Grapefruit juice combines the sweet and
tangy flavour of the orange and shaddock and also pro-
vides up to 69% of the RDA for vitamin C along with as
many as 250 mg of Potassium [1].
However, the wide consumption of grapefruit juice can-
not entirely be attributed to its taste, and nutritive value.
In fact, much of the enthusiasm in its use stems from med-
ical research that has suggested that grapefruit juice
reduces atherosclerotic plaque formation [2] and inhibits
breast cancer cell proliferation and mammary cell tumor-
igenesis [3,4]. Traditionally grapefruit juice has been
found to contain antioxidant, antinitrosaminic, antisep-
tic, aperitif, cardiotonic, detoxicant, hypocholesterolemic,
sedative and stomachic activities. In the light of its above
activities, it has been traditionally indicated throughout
time for anorexia, bacteria, benign prostatic hypertrophy,
cancers (breast, colon, prostate, lung, skin and throat),
candida, cold, diabetes, dysuria, high cholesterol, infec-
tion, insomnia, mycobacterium, mycosis, nervousness,
pseudomonas, rheumatism, staphylococcus and yeast.
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However, as many as fifteen years ago, investigators found
that grapefruit juice can markedly augment oral drug bio-
availability. This was an unexpected observation from an
interaction study between the dihydropyridine calcium
channel antagonist, felodipine, and ethanol in which
grapefruit juice was used as a flavour supplement to mask
the taste of the ethanol [5]. Studies that followed, con-
firmed that grapefruit juice significantly increased the oral
bioavailability of felodipine [6,7]. Subsequent studies
probed the constituents of grapefruit juice, its interaction
with various other drugs and the mechanisms of action of
those interactions. Several grapefruit juice-drug interac-
tions were discovered and these remain a potential con-
cern especially since the juice and drugs are often
consumed together at breakfast. An increasing number of
adverse drug reactions might be avoided on the basis of
knowledge about the interaction of grapefruit juice and
relevant drugs. Therefore, patients need to be educated
about the hazards (and advantages) of grapefruit interac-
tion with medication. In recent years, more drugs have
been investigated for their interaction with grapefruit juice
and new models have been proposed for the mechanism
of such interaction. This article presents a simplistic sum-
mary of most examples of such interactions and also
explores the phytochemistry and possible mechanisms of
action involved in drug-grapefruit juice interactions in
light of recent studies on this subject.
Mechanism of action
The mechanism of action of this interaction involves inhi-
bition of the CYP 3A4, a member of the cytochrome P 450
(CYP) enzyme system. CYP is a large multigene family of
heme-containing enzymes located in the endoplasmic
reticulum of cells throughout the body. It is especially
concentrated in the liver and intestinal wall where it is
involved in oxidative biotransformation of various
endogenous and exogenous substances. CYP 3A isoforms
constitute 70% of CYP enzymes in enterocytes [8,9]. P-
glycoprotein (Pgp), a member of the ABC (adenosine tri-
phosphate-binding cassette), is another membrane trans-
porter located in the apical brush border of enterocytes.
Once taken up by the enterocytes, a lipophilic drug may
be metabolized by CYP 3A4 or be pumped back into the
lumen by the Pgp. Hence the oral delivery of many drugs
is limited by the actions of CYP 3 A4 or Pgp. Metabolism
by the CYP 3A4 will also occur in the liver before the drug
finally enters the systemic circulation. Grapefruit juice
causes inhibition of CYP 3A4 and thus serves to increase
the bioavalability of the drug by decreasing its pre-sys-
temic metabolism [10]. This action is in essence, similar
to that caused by CYP-inhibiting drugs like itraconazole,
ketoconazole and erythromycin [11-13].
Grapefruit juice causes quick and irreversible sustained
inhibition of the CYP system, possibly by greatly acceler-
ating the degradation of these enzymes while also reduc-
ing translation from its mRNA. However, the process of
transcription of mRNA from the cell DNA is not affected.
Overall, grapefruit juice reduces the levels of CYP 3A4 in
the cells by as much as 47% within four hours of ingestion
of grapefruit juice with the resultant increased bioavaila-
bility being maintained for as long as 24 hours, by which
time 30% of its effect is still detectable [14-17]. It has been
observed that decreased content of CYP3A4 was not asso-
ciated with increased CYP3A4 mRNA, probably indicating
the absence of a feedback mechanism for CYP3A4 expres-
sion. Restoration of CYP3A4 activity would therefore
require denovo synthesis or enterocyte replacement,
accounting for the prolonged duration of the actions of
grapefruit juice [18].
Grapefruit juice shows a high variability of the magnitude
of effect among individuals. This variability is dependent
upon inherent differences in enteric CYP3A4 protein
expression such that individuals with highest baseline
CYP3A4 have the highest proportional increase [19,20].
However, the effects of grapefruit juice are predominantly
on the intestinal CYP rather than hepatic CYP. This is
shown by the fact that most of the drugs that are involved
in interaction with grapefruit juice undergo their primary
metabolism at the intestinal level and in usual quantity,
grapefruit juice does not affect the pharmacokinetics of
these drugs when they are administered intravenously.
Furthermore, while it increases the area under the plasma
concentration-time curve (AUC), it has no significant
effect on the half life of the drugs [10,21-23].
In contrast to the clear inhibitory effects of grapefruit juice
on CYP 3A4, the effects of grapefruit juice on Pgp are con-
troversial, ranging from activation to inhibition. Earlier
results have shown grapefruit juice to cause activation of
Pgp in vitro [24]. Any such activation in vivo will mean a
greater efflux of the drug back into the lumen, thereby
decreasing the oral bioavailability of that drug and at least
partially, if not completely offsetting the effects produced
by the inhibition of CYP system of enzymes. This is taken
as an explanation for the less-than-expected increase in
the bioavailability of drugs that are established substrates
of Pgp [24]. However, grapefruit juice does not change the
absorption of digoxin, a prototypical P-glycoprotein sub-
strate, likely because it has high inherent oral bioavailabil-
ity [17,25]. However, recent studies have demonstrated
the inhibition of Pgp by grapefruit juice both by its down-
regulation and inhibition of function [26,27]. For exam-
ple, grapefruit juice increases the bioavailability of
cyclosporine. This effect is thought to be primarily though
Pgp inhibition (instead of CYP3A4 inhibition) since
orange juice mediated reduction in enterocyte CYP3A4
concentrations did not produce a similar increase in bio-
availability [17]. In fact, grapefruit juice has also shownNutrition Journal 2007, 6:33 http://www.nutritionj.com/content/6/1/33
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inhibition of multidrug resistant protein 2 (MRP2), an
efflux protein closely related to Pgp in terms of its expres-
sion and function [26].
Yet, in spite of all what is known, the mechanism of action
of grapefruit juice-drug interaction requires further inves-
tigation. Investigators still need to determine for certainty
any in vivo effect of grapefruit juice on Pgp. One study
[28] has also reported the action of grapefruit juice inde-
pendent of its actions on Pgp and CYP 3A4. This also
requires further investigation. Similarly, grapefruit and
even orange juice have also recently been shown to be
potent in vitro inhibitors of a number of organic anion-
transporting polypeptides (OATPs) that are involved in
apical-to-basal transport of drugs in the small intestine
[17,18,25,29]. They were also found to decrease the
absorption of the non-metabolized OATP substrate, fex-
ofenadine hence pointing towards inhibition of intestinal
uptake transporters by fruit juices to decrease drug bioa-
vailability. This newly proposed mechanism of action and
its effect vis a vis various medications also demands fur-
ther investigation [25,29].
Assessment of the in vitro CYP inhibition potential for
these natural products has important implications for pre-
dicting the likelihood of natural product-drug interac-
tions if these products are taken concomitantly. The
susceptibility of CYP3A4 to modulation by food constitu-
ents may be related to its high level of expression in the
intestine, as well as its broad substrate specificity.
Reported ethnic differences in the activity of this enzyme
may be partly due to dietary factors. Food-drug interac-
tions involving CYP1A2, CYP2E1, glucuronosyltrans-
ferases and glutathione S-transferases have also been
documented, although most of these interactions are
modest in magnitude and clinically relevant only for
drugs that have a narrow therapeutic range. Recently,
interactions involving drug transporters, including P-glyc-
oprotein and the organic anion transporting polypeptide,
have also been identified. Hence a lot of food varieties
have the potential to require dosage adjustment to main-
tain drug concentrations within their therapeutic win-
dows, especially with drugs that have a high first pass
degradation [30]. Further research is needed to determine
the scope, magnitude and clinical importance of food
effects on drug metabolism and transport.
Relevant phytochemistry
Another area in which the search for definite answers con-
tinues, is the quest to find the active constituents of grape-
fruit juice that are responsible for its actions on CYP
enzyme systems and Pgp. The components of grapefruit
juice that are responsible for clinical drug interactions
have yet to be fully determined but the compounds
thought to be responsible for this action include flavo-
noid glycosides (narirutin, naringin, naringinen, querce-
tin, kaemferol, hesperidin, neohesperidin, didymin, and
poncirin) [8,31-34], furanocoumarins (6',7'-dihydroxy-
bergamottin, bergamottin) and sesquiterpen (nootka-
tone)[8,22,32,35,36].
Flavanoids exist in grapefruit juice in the form of glyco-
sides, with naringin being the most abundant. Upon
ingestion, these are converted to aglycones and sugars by
the action of intestinal flora. Being polyphenolic and elec-
tron rich, these compounds can theoretically inhibit the
CYP enzymes. However, studies have at most shown an in
vitro effect by these compounds on the these enzymes and
have failed to identify any in vivo effect by them [37,38],
leading to an implication that they are probably not the
main active ingredients of grapefruit juice [1,39]. Studies
have even failed to demonstrate any sort of activity in nar-
ingin although its metabolite naringinin was observed to
be active in vitro. Yet, because of their huge quantities in
grapefruit juice, and the fact that naringin is not present in
other citrus juices, flavanoids remain a subject of research.
The main focus at present, however, is on furanocou-
marins. This group includes Bergamottin, its derivative 6'
7' dihydroxybergamottin (DHB) and a host of other com-
pounds [40]. Controversy still exists on the degree of their
role in the inhibitory effects of grapefruit juice. Several
studies have shown DHB [23,35,40] and to an extent Ber-
gamottin [23] to be important contributors to the grape-
fruit juice effect. In one study, the inhibitory potency of
DHB and four recently isolated furanocoumarins, when
mixed with one another, almost approached that of grape-
fruit juice. Omission of any of the components resulted in
decreased potency, suggesting that all major furanocou-
marins contribute to the inhibitory effects of grapefruit
juice [40]. However, others have suggested that DHB and
Bergamottin are not the primary substances responsible
for inhibition of CYP activity clinically [41,42]. For now,
this topic also remains a subject of intense research.
Drug-grapefruit juice interactions
Anti-hypertensive drugs and amiodarone
1,4-Dihydropyridine calcium antagonists are lipid soluble
drugs used in the treatment of essential hypertension and
angina pectoris and metabolized in vivo by CYP3A4.
Since the effects of grapefruit juice were first noticed with
felodipine, this class of drugs has been intensively studied
with grapefruit juice. The degree to which the intestinal
CYP system metabolizes this class of drugs and affects
their oral bioavailability varies markedly. In a study done
by Lundahl J et al., it was found that the intake of grape-
fruit juice led to an increase in the oral bioavailability by
112% [43]. However, this study also found out that the
intravenous pharmacokinetics of felodipine were not sig-
nificantly altered with grapefruit juice. The main acuteNutrition Journal 2007, 6:33 http://www.nutritionj.com/content/6/1/33
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effect of the grapefruit juice on the plasma concentrations
of felodipine was believed to be mediated by inhibition of
gut wall metabolism. Grapefruit juice-felodipine interac-
tion increases with increasing frequency and amount of
grapefruit juice ingestion, hence it has been determined
that an interval of 2–3 days between grapefruit juice
intake and felodipine administration is necessary if the
interaction is to be avoided [44]. Blood pressure responses
to felodipine with grapefruit juice have also been assessed
in the elderly and the systolic and diastolic blood pres-
sures were found to be lower with grapefruit juice in the
single-dose state, whereas they were not different between
treatments in the steady-state dose [45]. The different
blood pressure results between the studies can be
explained by felodipine concentration-blood pressure
response relationships. The elderly should be particularly
cautioned about concomitant grapefruit juice and
felodipine ingestion.
In the benzothiazepine calcium channel antagonists
group, diltiazem has been found to have an increased bio-
availability on co administration of a single intake of
grapefruit juice. Inhibition of intestinal metabolism and/
or P-glycoprotein efflux transport was believed to be pos-
sibly responsible for this effect [46]. However in contrast
to this, another study showed the bioavailability to be
unchanged with grapefruit juice suggesting that factors
other than biotransformation may be contributing [47].
Compared with water, grapefruit juice increased the max-
imum concentration of nisoldipine and reduced the time
to reach maximum nisoldipine concentration [48]. How-
ever, the effects of grapefruit pulp intake were smaller
than those produced by grapefruit juice intake, indicating
that grapefruit pulp and juice have different effects on the
pharmacokinetics [49].
A clinical study was performed to see the duration of this
interaction in the body. Eight healthy volunteers were
given grapefruit juice at 14, 38, 72 and 96 hours. Com-
pared with the control group, the maximum plasma con-
centration of nisoldipine was significantly increased after
grapefruit juice intake in at 0 and 14 hours, and the
plasma concentration was significantly increased at each
time till 72 hours [50]. It is therefore necessary to with-
hold grapefruit juice for at least 3 days before administra-
tion of the drug to prevent grapefruit juice -nisoldipine
interaction.
Regarding verapamil, there are conflicting reports about
its interaction with grapefruit juice. One study showed an
increase in its bioavailability at steady state [51] while
another showed no significant change in pharmacokinet-
ics on a single administration.
ACE-inhibitors like enalapril, captopril, lisinopril and
ramipril have not shown any interaction with grapefruit
juice although such an interaction might be possible with
angiotensin II type 1 receptor antagonists like losartan
and valsartan [18]. Thiazide diuretics and alph 1 adrener-
gic antagonists (doxazosin, terazosin, prazosin) have also
shown no interaction with grapefruit juice [18].
Amiodarone, an antiarrythmic, is metabolized by CYP3A
to N-desethylamiodarone (N-DEA), a metabolite more
potent than the parent drug [17]. On interaction with
grapefruit juice, there has been shown to be complete
inhibition of N-DEA production [52] leading to an overall
decrease in the arrythmogenic side effects of amiodarone
[17]. These results are in agreement with in vitro data
pointing to the involvement of CYP3A in the metabolism
of amiodarone and other Ca antagonists, suggesting that
this interaction should be taken into account when pre-
scribing this antiarrhythmic drug. Similarly grapefruit
juice has been found to increase oral nimodipine bioa-
vailability [53]. The same cannot be said of amlodipine,
on which grapefruit juice has no appreciable effect [54].
One of the possible active ingredients in commercial
grapefruit juice is Bergamottin, as mentioned before. This
was determined after studying the effects of the furano-
coumarin derivative on nifedipine (NFP) pharmacokinet-
ics, suggesting that bergamottin in grapefruit might be the
substance that elevates the NFP plasma concentrations
[55].
Further studies have also been done to determine if even
unprocessed grapefruit could cause drug interactions. It
has been shown that unprocessed grapefruit can cause a
drug interaction with felodipine [56]. 6', 7'-Dihydroxyber-
gamottin and naringin were implicated to be more impor-
tant in this case because they are present in higher
concentrations in grapefruit extracts.
Antimicrobials
With antivirals, authors concluded that concomitant
administration of grapefruit juice increases gastric pH and
delays indinavir absorption but does not uniformly affect
the systemic bioavailability of indinavir in HIV-infected
subjects [57,58]. Similarly grapefruit juice has been
shown clinically to not significantly affect amprenavir
pharmacokinetics [59]. It is suggested that this may be
because the primary metabolism of these drugs is not in
the small intestine.
On the other hand regarding saquinavir, it has been
shown that grapefruit juice increases the bioavailability of
saquinavir without affecting its clearance, suggesting that
inhibition of intestinal CYP3A4 may contribute [60]. And
since the antiretroviral effect of saquinavir is dose-Nutrition Journal 2007, 6:33 http://www.nutritionj.com/content/6/1/33
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dependent, it has been suggested that inhibition of
CYP3A4 may represent a way to enhance its effectiveness
without increasing the dose.
Amongst anti malarials, grapefruit juice significantly
increases the oral bioavailability of artemether but does
not prevent the time-dependent reduction in bioavailabil-
ity or elimination half-life, suggesting a role for intestinal
CYP3A4 in the presystemic metabolism of artemether
[61,62]. Similar results have also been seen after a single
oral dose of praziquantel with 250 ml of grapefruit juice
[63].
Quinine appears to be unaffected in its pharmacokinetics.
Since quinine is a low clearance drug with a relatively high
oral bioavailability, and is primarily metabolised by
human liver CYP3A4, the lack of effect of grapefruit juice
on quinine pharmacokinetics again supports the view that
the site of CYP inhibition by grapefruit juice is mainly in
the gut [17,64]. However for quinidine, grapefruit juice
reduces its total clearance and increases the elimination
half-life by 19% [65].
In antibiotics, administration of grapefruit juice increased
the time to peak concentration of clarithromycin but did
not affect other pharmacokinetic parameters [66] while in
antiparasitics, albendazole showed an increase in bioa-
vailability upon administration of grapefruit juice [67].
Benzodiazepines and CNS drugs
A marked interaction between oral midazolam and grape-
fruit juice has been found and the data is consistent again
with a reduced first-pass metabolism of midazolam,
resulting in increased bioavailability of midazolam
[68,69]. The clinical importance of this is especially for
patients with other causes for increased midazolam bioa-
vailability such as advanced age, cirrhosis of the liver, and
administration of other inhibitors of cytochrome P450.
Thus, patients with liver cirrhosis are more dependent on
the intestine for metabolism of CYP3A4 substrates than
subjects with normal liver function. Another important
implication of this interaction is in dentistry. Oral mida-
zolam is a frequently used sedative in pediatric dentistry.
Although an oral form of midazolam is now commer-
cially available, some practitioners continue to use the IV
midazolam as an oral medication. If the injectible form of
midazolam is administered orally, its bitter taste requires
the use of a flavoring agent like grapefruit juice. This
results in increased blood plasma levels of midazolam
causing excessive levels of sedation for the pediatric
patient. Grapefruit juice therefore should be contraindi-
cated for use with oral midazolam especially in such
patients [70]. Similar results have also been seen with tri-
azolam [71].
One study however, did show that grapefruit juice did not
have any particular interaction with oral doses of 10 mg
midazolam and 0.25 mg triazolam in healthy young sub-
jects [72]. However, since more studies have determined
increases in midazolam and triazolam bioavailbility,
grapefruit juice should be administered with caution with
these drugs. However, alprazolam remains unaffected in
pharmacokinetics or pharmacodynamics due to its high
bioavailability [73].
Among antipsychotics, clozapine remained unaffected
after consumption of regular-strength grapefruit juice,
usually taken as 250 mL b.i.d., for 14 days [74]. One rea-
son for this is that enzymes other than CYP3A4 also medi-
ate clozapine disposition. Haloperidol remains
unaffected by grapefruit juice [75].
In anti convulsants, grapefruit juice increases the bioavail-
ability of carbamazepine [76] but does not affect the phar-
macokinetics of phenytoin [77].
Grapefruit juice considerably increases plasma buspirone
concentrations [78] and also increases sertraline bioavail-
ability [79]. Grapefruit juice therefore should be contrain-
dicated during administration of buspirone and
sertraline.
Antihistamines and Serotonin Analogs
A number of studies have shown that a single glass of
grapefruit juice produced an individual-dependent, varia-
ble increase in the systemic bioavailability of cisapride by
inhibition of intestinal cytochrome P450 3A4 (CYP3A4)
activity. [80-82] It has therefore been recommended that
concomitant use of high amounts of grapefruit juice with
cisapride should be avoided, at least in patients with risk
factors for cardiac arrhythmia.
The effect of grapefruit juice on racemic nitrendipine was
also to increase its bioavailability and it was found that it
inhibits the stereoselective metabolism of nitrendipine in
humans [83].
Regarding terfenidine, the ingestion of grapefruit juice
leads to its enhanced systemic bioavailability [84,85].
This is especially important because the raised levels of
terfenidine can prolong the QT interval in the electrocar-
diogram sufficiently to precipitate the ventricular arrhyth-
mia of Torsade-des-pointes [86]. Incidentally, both
terfenidine and cisapride have been globally withdrawn
from the market due to serious cardiac arrythmias precip-
itated by their interaction with other drugs if simultane-
ously taken.Nutrition Journal 2007, 6:33 http://www.nutritionj.com/content/6/1/33
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Statins and other cholesterol-lowering agents
Taking simvastatin first, the active ingredient bergamottin
has been shown to inhibit simvastatin (SV) metabolism
and increase the serum concentrations of simvastatin and
its active metabolite simvastatin acid, and, to a lesser
extent, those of active and total HMG-CoA reductase
inhibitors [87,88]. The probable mechanism of this inter-
action was also the inhibition of CYP3A4-mediated first-
pass metabolism of simvastatin by grapefruit juice in the
small intestine. Bergamottin (BG) and naringenin (NRG)
could therefore be applied as markers in food-drug inter-
action studies in order to adjust posology and the dose of
simvastatin should be accordingly reduced.
Another study further found out that, when simvastatin is
taken 24 hours after ingestion of "high-dose" grapefruit
juice, the effect on the concentration of simvastatin is only
about 10% of the effect observed during concomitant
intake of grapefruit juice and simvastatin. It was also
shown that the interaction potential of even high
amounts of grapefruit juice with CYP3A4 substrates dissi-
pates within 3 to 7 days after ingestion of the last dose of
grapefruit juice [89].
The grapefruit juice effect has also been studied on lovas-
tatin. Lovastatin and its active metabolite, lovastatin acid
had greatly increased serum concentrations after grape-
fruit juice administration [90]. However, one other study
has shown a minimal effect of a glass of regular-strength
grapefruit juice on plasma concentration after a 40 mg
evening dose of lovastatin [91].
Although grapefruit juice also increases the AUC of atorv-
astatin, the actual increase in activity is fairly modest, pos-
sibly due to a simultaneous effect of decreasing the AUC
of active metabolites of atorvastatin [17]. Regardless,
grapefruit juice should not be concomitantly ingested
with atorvastatin, lovastatin or simvastatin. On the other
hand, pravastatin, fluvastatin and rosuvastatin are three
statin drugs that have been shown not to interact with
grapefruit juice [18]. These may be useful alternatives in
settings where there is a concern regarding potential inter-
action with grapefruit juice.
Other cholesterol-lowering agents like nicotinic acid and
common fibric acid derivatives and bile acid sequestrants
have shown no interaction, and therefore may be safely
used, with grapefruit juice [18].
Chemotherapeutics
In patients with autoimmune diseases, the effect of
chronic grapefruit juice administration on steady state
blood concentrations of cyclosporine and metabolites is
an increase in both parent and metabolite profiles [92].
This interaction was studied in renal transplant recipients.
Administration of cyclosporine with grapefruit juice com-
pared with water induced a moderate, butsignificant
increase in the systemic exposure of cyclosporine [93,94].
Most of these studies involving cyclosporine were done
on adult patients. However, one study was also done in
the paediatric population. This study showed that altera-
tions in cyclosporine absorption and elimination only
occur with concurrent grapefruit juice ingestion when sta-
ble pediatric renal transplant patients are taking the oral
cyclosporine solution, but not the microemulsion formu-
lation [95].
Regarding prednisolone and etoposide, grapefruit juice
has been found to have no significant effect on the metab-
olism of prednisolone [96] but in the case of etoposide, it
has been shown to decrease its bioavailability [97].
Conclusion
In light of the wide ranging effects of grapefruit juice on
the pharmacokinetics of various drugs, physicians need to
be aware of these interactions and should make an
attempt to warn and educate their patients regarding
potential consequences of concomitant ingestion of these
two items. Patient-to-patient variability should be kept in
mind and elderly should be particularly warned about
these interactions since they are more prone to grapefruit
juice-drug interactions [17]. Physicians should also con-
sider using these effects to their own advantage in order to
reduce the dosage requirements of certain drugs. How-
ever, since further research is required into the mechanism
of action of grapefruit juice, it is still premature to recom-
mend it as an adjunctive booster with other drugs.
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